EXPAREL for Minimally Invasive Supracervical Hysterectomies
Status:
Unknown status
Trial end date:
2019-06-30
Target enrollment:
Participant gender:
Summary
The aim of the of the study is a reduction in minimally invasive supracervical hysterectomy
postsurgical pain, which may result in less need for supplemental opioid pain medications,
fewer opioid related adverse events, and a better recovery experience for patients, which may
offer an economic benefit to health care systems.
Intracervical preoperative dose of Exparel during minimally invasive (robotic--assisted or
traditional laparoscopy) supracervical hysterectomy reduces cumulative pain scores for up to
24 hours and reduces overall requests for break through (additional) analgesia with opioid
consumption compared with placebo.